Decoding Cytoplasmic Vacuolization: Unraveling the Diagnostic Challenges of VEXAS Syndrome
Taner Tan +5 more
doaj +1 more source
Drug-Free Remission of VEXAS Syndrome Without Stem Cell Transplantation. [PDF]
Warren J, Smylie C, Milne A.
europepmc +1 more source
Promise of Jak Inhibition in the Management of VEXAS, Case Report with Review of the Literature
Zeinab Alnahas,1 Sujata Sarkar,1 Kevin T Trowell,1 Lisa Soltani,2 Sreekanth Vasireddy1 1Tucson Medical Center, Tucson, AZ, USA; 2El Rio Community Health Center, Tucson, AZ, USACorrespondence: Zeinab Alnahas, Tucson Medical Center, 5301 E Grant Road ...
Alnahas Z +4 more
doaj
VEXAS syndrome: a comprehensive clinicopathologic and genetic analysis of a predominantly Indian cohort. [PDF]
Chinnam D +25 more
europepmc +1 more source
The ubiquitin-activating enzyme, UBA1, as a novel therapeutic target for AML
Barghout, Samir H., Schimmer, Aaron D.
openaire +2 more sources
DP096 | COMBINATION OF 5-AZACITIDINE AND RUXOLITINIB IN VEXAS SYNDROME: A RETROSPECTIVE STUDY
Introduction: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is an autoinflammatory condition caused by somatic UBA1 mutations in hematopoietic progenitors, frequently associated with cytopenias and myelodysplastic syndromes ...
G.M. Bergonzi +9 more
doaj
A neurologist's guide to VEXAS syndrome: Differentiating somatic autoinflammation from autoimmune mimics. [PDF]
Mitsoudis N +4 more
europepmc +1 more source
The profile of clinical and laboratory features of Chinese VEXAS syndrome patients with hematological abnormalities: a single-center case series. [PDF]
Ren X +15 more
europepmc +1 more source
VEXAS Syndrome: Clinical Features, Hematologic Involvement, and Clinical Outcomes of Current and Emerging Therapies. [PDF]
Assavarittirong C +3 more
europepmc +1 more source
CDH4/UBA1/RBMX axis promotes polycystic ovary syndrome progression through YAP1 activation. [PDF]
Xu N +8 more
europepmc +1 more source

